THE #1
PRESCRIBED CAR-T CELL THERAPY FOR RRMM1*

GET IN
TOUCH
CARVYKTI® demonstrated aDown 59%

Reduction in the risk of disease
progression or death
vs standard therapy (DPd or PVd)2†

(HR=0.41; 95% CI: 0.30-0.56; P<0.0001)

EXPLORE THE CARTITUDE-4
LONG-TERM FOLLOW-UP ANALYSIS

CARVYKTI® is a B-cell maturation antigen (BCMA)–directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 1 prior line of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMID), and are refractory to lenalidomide.

NCCN

CATEGORY 1

THE FIRST AND ONLY CAR-T CELL THERAPY TO BE DESIGNATED AS NCCN CATEGORY 1 in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for multiple myeloma after 1 prior therapy3

Listed under “Therapy for Previously Treated Multiple Myeloma Relapsed/Refractory Disease After 1-3 Prior Therapies” as an option after 1 prior line of therapy, including an IMID and a PI, and refractory to lenalidomide.3

Additionally, ciltacabtagene autoleucel is designated as Category 2A after 3 prior therapies.3

Study Design

Learn More About
Patient Eligibility 

See Eligibility Criteria

Study Design

Review the CARVYKTI®
Safety Profile

See the Safety Profile

Study Design

Learn About Resources for
Access and Reimbursement

Get Access Resources

Resources Icon

Find Educational Resources to
Support Your Patients

Get Patient Resources

CARTITUDE-4 is a randomized, open label, multicenter controlled study evaluating the efficacy and safety of CARVYKTI® for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma, who previously received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. A total of 419 patients were randomized 1:1 to receive either CARVYKTI® (n=208) or standard therapy which included daratumumab, pomalidomide, and dexamethasone (DPd) or bortezomib, pomalidomide, and dexamethasone (PVd) selected by physician prior to randomization based on patient’s prior antimyeloma therapy (n=211). The primary efficacy measure was PFS analyzed based on the Intent-to-Treat Analysis Set.2

2L=second-line; CAR-T=chimeric antigen receptor-T cell; CI=confidence interval; HR=hazard ratio; NCCN=National Comprehensive Cancer Network® (NCCN®); PFS=progression-free survival.

*From January 2021 to November 2024.

†15.9 months follow-up (Intent-to-Treat Analysis Set).

Learn More About CARVYKTI®

GET IN TOUCH